Véronique Crutel

Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

Véronique Crutel, Pierre‐François Pénélaud, Cristina Albarrán Severo et al. · Journal of Autism and Developmental Disorders · 2020 · 33 citations · Full text

Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase <scp>III</scp> studies

Joaquín Fuentes, Mara Parellada, Christina Georgoula et al. · Autism Research · 2023 · 32 citations · Full text

Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50 mg or fluoxetine 20–40 mg in Asian out-patients with major depressive disorder

Liang Shu, Ahmad Hatim Sulaiman, Yu‐Shu Huang et al. · Asian Journal of Psychiatry · 2013 · 19 citations

Efficacy of Tianeptine 25–50 mg in Elderly Patients With Recurrent Major Depressive Disorder

Robin Emsley, Antti Ahokas, A. González Suárez et al. · The Journal of Clinical Psychiatry · 2018 · 12 citations

A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics

Christina Georgoula, Maite Ferrín, Bożena Pietraszczyk-Kędziora et al. · Child Psychiatry & Human Development · 2022 · 12 citations

Syndromic Autism, Participant Baseline Characteristics, Pharmacology +8